| RAST tables updated |
|
 |
|
2025/07/14 |
| Updated guidance on Infective endocarditis |
|
|
|
2025/07/10 |
| SOP 9 updated |
SOP 9.3 updated to 9.4. |
|
|
2025/07/10 |
| VetCAST Rationale documents published |
|
|
|
2025/05/22 |
| Daptomycin in Enterococcus |
Daptomycin in endocarditis and bloodstream infections caused by enterococci (updated April 2025) |
|
|
2025/04/23 |
| RAST breakpoints and methods updated |
- the breakpoint table was updated - new information on how to screen for and characterize benzylpenicillin resistance in Streptococcus pneumoniae added.
- files describing the correlation between RAST zone diameters and reference MIC values were updated
- methods document updated
- document describing the detection of specific resistance mechanisms updated
- document proposing how to implement RAST in the clinical laboratory updated. |
|
|
2025/03/18 |
| All calibration files - MIC vs. zone diameters - updated for 2025 |
All calibration files updated for 2025. For 2025 S. dysgalactiae is added. |
|
|
2025/03/17 |
| Update of SOP 12 |
The SOP 12 on the "Process to Submit Disk Content (Potency) Data for Joint CLSI-EUCAST Working Group Review and Approval" was updated to 12.1 |
|
|
2025/03/11 |
| Updated guidance on the use cephalosporins for S. aureus |
|
|
|
2025/02/21 |
| M. tuberculosis MIC reference testing available from EUCAST AMST |
Following standard consultation, the EUCAST AMST reference protocol MIC determination of M. tuberculosis has now been released in the Mycobacteria methods section |
|
|
2025/02/20 |
| Rationale document template for pharmaceutical companies |
Companies are requested to complete a "company rationale document" to aid the EUCAST process. A template for how has been available for many years. It is now revised. |
|
|
2025/02/19 |
| ECOFFinder software removed from website |
ECOFFinder. The previously available ECOFFinder program is no longer accessible on the EUCAST website because, according to EUCAST procedures (SOP 10.2), setting ECOFFs or TECOFFs on single or already aggregated distributions is not acceptable according to EUCAST recommendations. Software and procedures to set individual ECOFFs on 5 or preferably more accepted distributions result in mean ECOFFs with confidence limits and an analysis of the quality of the procedure leading to the establishment of a formal ECOFF recognized by EUCAST in the processes for setting breakpoints, screening for resistance etc.
Questions about this can be directed to the curators via the question form EUCAST wild type distributions. |
|
|
2025/02/05 |
| NAC update for Greece |
The presentation of the Greek NAC updated |
|
|
2025/01/23 |
| SOP 11 revised |
|
|
|
2025/01/21 |
| Clinical breakpoints 2025 |
Yearly update of EUCAST breakpoint tables. News highlighted in pale yellow or with underlining of text. |
|
|
2025/01/01 |
| Updated documents on disk diffusion methodology |
|
|
|
2025/01/01 |
| QC criteria for cefepime-enmetazobactam and aztreonam-avibactam |
|
|
|
2024/12/21 |
| Breakpoint table 15.0 on consultation |
|
|
|
2024/12/05 |
| Endocarditis AST guidelines |
Guidance for the use of the new endocarditis breakpoints (released as part of the v 15.0 (2025) breakpoint table) is released. |
|
|
2024/12/05 |
| Antifungal breakpoints and updated 2 Dec 2024 |
The breakpoint tables for antifungal agents have been revised. |
|
|
2024/12/02 |
| Antifungal overview of breakpoints and ECOFFs revised |
|
|
|
2024/12/02 |
| Anidulafungin and Micafungin rationale documents updated 2024 |
|
|
|
2024/11/25 |
| Endocarditis breakpoints |
Following the now finalised consultation, the comments from colleagues and responses from EUCAST are now published. |
|
|
2024/11/20 |
| Updated guidance on S. maltophilia |
|
|
|
2024/11/15 |
| Response to public consultation |
EUCAST comments and responses to the public consultation on changing breakpoints for S. pneumoniae and Streptococcus viridans published. |
|
|
2024/10/24 |
| RAST tables - Error related to Acinetobacter corrected |
An error related to recommendations for Acinetobacter baumannii and ciprofloxacin corrected. |
|
|
2024/09/23 |
| Aminoglycoside rationale documents updated |
|
|
|
2024/09/19 |
| General consultation on proposed breakpoints for endocarditis |
The public consultation is open between 14 Sept and 25 Oct, 2024. |
|
|
2024/09/14 |
| Cefiderocol has been addded to "When there are no breakpoints" |
|
|
|
2024/09/03 |
| New Rationale Document |
RDs for aztreonam-avibactam and cefepime-enmetazobactam available |
|
|
2024/07/04 |
| RAST from EUCAST with breakpoints for Salmonella enterica |
EUCAST has developed the Enterobacterales RAST further to include 4, 6, 8 and 16-20 h breakpoints also for Salmonella enterica. Some QC criteria were also updated. |
|
|
2024/07/04 |
| Expert rules updated |
Expert rules updated for Enterobacterales and Enterococcus. |
|
|
2024/06/30 |
| Updated guidance document |
"Intravenous use of fosfomycin" updated 28 May, 2024.
See guidance documents. |
|
|
2024/05/28 |
| Aztreonam-avibactam and cefepime-enmetazobactam breakpoints available |
Breakpoints published as addenda to the regular breakpoint table 14.0, 2024. |
|
|
2024/05/22 |
| The Belgian NAC presented |
The Belgian NAC (National AST Committee) is presented. |
|
|
2024/05/18 |
| New consultations |
New consultation published. |
|
|
2024/05/07 |
| EUCAST advice on the development of reference methods for MIC testing of new agents |
The development of new agents require agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions, ECOFFs and routine susceptibility testing correlates. EUCAST and CLSI both favour the unadulterated use of ISO recommended reference broth microdilution for this purpose, and only occasionally is there good reason to deviate from this. When this is considered necessary it is strongly adviced that this is with the agreement and full understanding of standards committees and agencies, such as CLSI, EUCAST, FDA and EMA. |
|
|
2024/04/24 |
| When there are no breakpoints - revised 29 February 2024 |
|
|
|
2024/02/29 |
| Advising pharmaceutical industry |
The advice to pharmaceutical industry has been further developed. Go to the "Information for industry" page. |
|
|
2024/02/14 |
| Rezafungin Rationale Document published |
|
|
|
2024/02/11 |
| Updated guidance on ATU |
|
|
|
2024/02/08 |
| Revised "EUCAST response to the fosfomycin consultation" |
Because of a printing error in this document a new version was uploaded. |
|
|
2024/02/06 |
| ECCMID 2023 EUCAST posters available |
|
|
|
2024/01/10 |
| Maps updated for 2024 EUCAST uptake |
|
|
|
2024/01/10 |
| Graphs to illustrate ATUs updated 2024 |
EUCAST provides a yearly update of the ATUs in relation to zone diameter and MIC distributions. The 2024 update now available. |
|
|
2024/01/09 |
| Files demonstrating the correlation between MIC and zone diameters now updated |
|
|
|
2024/01/09 |
| Several Rationale Documents updated |
|
|
|
2024/01/05 |
| The 2024 EUCAST breakpoint table available for consultation |
The period for consultation is 5 - 19 December, 2024. Comments and questions should be addressed to erika.matuschek[at]eucast.org or gunnar.kahlmeter[at]eucast.org. |
|
|
2023/12/05 |
| Fosfomycin - response to consultation and guidance on IV use |
|
|
|
2023/12/05 |
| New fosfomycin IV rationale document published |
|
|
|
2023/11/23 |
